Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company is now reporting the full data set of a Phase 2a Study of Ifenprodil in treatment for idiopathic pulmonary fibrosis and chronic cough. Moreau told Proactive the company saw positive data as this study which measured efficacy in lung function and patient-reported outcomes of both IPF and cough. The data showed statistically significant improvements in measures of cough. As for IPF the preservation of lung function determined no worsening of forced vital capacity over 12 weeks.
Algernon Pharmaceuticals releases positive data from study on Ifenprodil for IPF and Chronic Cough
